Ident. | Authors (with country if any) | Title |
---|
000B80 (2014) |
Alexandro Gianforcaro [Canada] ; Mazen J. Hamadeh [Canada] | Vitamin D as a Potential Therapy in Amyotrophic Lateral Sclerosis |
000B83 (2014) |
Stéphanie Bissonnette [Canada] ; Sophie Muratot [Canada] ; Nathalie Vernoux [Canada] ; François Bezeau [Canada] ; Frédéric Calon [Canada] ; Sébastien S. Hebert [Canada] ; Pershia Samadi [Canada] | The effect of striatal pre-enkephalin overexpression in the basal ganglia of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease |
001485 (2012) |
WEI SONG [Canada] ; Hillel Zukor [Canada] ; Shih-Hsiung Lin [Canada] ; Adrienne Liberman [Canada] ; Ayda Tavitian [Canada] ; Jeannie Mui [Canada] ; Hojatollah Vali [Canada] ; Carine Fillebeen [Canada] ; Kostas Pantopoulos [Canada] ; Ting-Di Wu [France] ; Jean-Luc Guerquin-Kern [France] ; Hyman M. Schipper [Canada] | Unregulated brain iron deposition in transgenic mice over-expressing HMOX1 in the astrocytic compartment |
001493 (2012) |
D. Domenger [Canada] ; D. Dea [Canada] ; L. Theroux [Canada] ; L. Moquin [Canada] ; A. Gratton [Canada] ; J. Poirier [Canada] | The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain |
001525 (2012) |
D. W. Luchtman [Canada] ; Q. Meng [Canada] ; C. Song [Canada, République populaire de Chine] | Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease |
001536 (2012) |
S. Al-Sweidi [Canada] ; M. Morissette [Canada] ; T. Di Paolo [Canada] | Effect of Oestrogen Receptors on Brain NMDA Receptors of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mice |
001908 (2011) |
Darcy Litteljohn [Canada] ; Eric Nelson [Canada] ; Cheri Bethune [Canada] ; Shawn Hayley [Canada] | The effects of paraquat on regional brain neurotransmitter activity, hippocampal BDNF and behavioural function in female mice |
001961 (2011) |
Sara Kost [Canada] ; CHAO SUN [Canada] ; WEI XIONG [Canada] ; Kathryn Graham [Canada] ; Carol E. Cass [Canada] ; James D. Young [Canada] ; Benedict C. Albensi [Canada] ; Fiona E. Parkinson [Canada] | Behavioral effects of elevated expression of human equilibrative nucleoside transporter 1 in mice |
001D17 (2010) |
QINGJIA MENG [Canada] ; Dirk W. Luchtman [Canada] ; BOUCHAIB EL BAHH [Canada] ; Jeffrey A. Zidichouski [Canada] ; JUN YANG [Canada] ; CAI SONG [Canada] | Ethyl-eicosapentaenoate modulates changes in neurochemistry and brain lipids induced by parkinsonian neurotoxin 1-methyl-4-phenylpyridinium in mouse brain slices |
001D30 (2010) |
C. Gibrat [Canada] ; M. Bousquet [Canada] ; M. Saint-Pierre [Canada] ; D. Levesque [Canada] ; F. Calon [Canada] ; C. Rouillard [Canada] ; F. Cicchetti [Canada] | Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor |
001D31 (2010) |
Mélanie Bousquet [Canada] ; Claire Gibrat [Canada] ; Mélissa Ouellet [Canada] ; Claude Rouillard [Canada] ; Frédéric Calon [Canada] ; Francesca Cicchetti [Canada] | Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases |
002060 (2009) |
Grace Lee [Canada] ; Tony Chu [Canada] ; Christopher A. Shaw [Canada] | The primary locus of motor neuron death in an ALS-PDC mouse model |
002110 (2009) |
Claire Gibrat [Canada] ; Martine Saint-Pierre [Canada] ; Mélanie Bousquet [Canada] ; Daniel Levesque [Canada] ; Claude Rouillard [Canada] ; Francesca Cicchetti [Canada] | Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and α-synuclein inclusions |
002117 (2009) |
Dirk W. Luchtman [Canada] ; DI SHAO [Canada] ; CAI SONG [Canada] | Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease |
002379 (2008) |
Anthony P. Nicholas [États-Unis] ; Farah D. Lubin [États-Unis] ; Penelope J. Hallett [États-Unis] ; Padmapriya Vattem [États-Unis] ; Paula Ravenscroft [Royaume-Uni] ; Erwan Bezard [France] ; SHAOBO ZHOU [Royaume-Uni] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] ; J. David Sweatt [États-Unis] ; David G. Standaert [États-Unis] | Striatal histone modifications in models of levodopa-induced dyskinesia |
002537 (2007) |
Anne M. Landau [Canada] ; Edouard Kouassi [Canada] ; Rosmarie Siegrist-Johnstone [Canada] ; Julie Desbarats [Canada] | Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle |
002638 (2007) |
Mélanie Bourque [Canada] ; BIN LIU [États-Unis] ; Dean E. Dluzen [États-Unis] ; Therese Di Paolo [Canada] | Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity |
002903 (2006) |
Pepijn Van Den Munckhof [Canada] ; Francois Gilbert [Canada] ; Michel Chamberland [Canada] ; Daniel Levesque [Canada] ; Jacques Drouin [Canada] | Striatal neuroadaptation and rescue of locomotor deficit by L-dopa in aphakia mice, a model of parkinson's disease |
002918 (2006) |
Reyniel Cruz-Aguado [Canada] ; Daniella Winkler ; Christopher A. Shaw | Lack of behavioral and neuropathological effects of dietary β-methylamino-L-alanine (BMAA) in mice |
002A94 (2005) |
J. Lewis [États-Unis] ; G. Bench [États-Unis] ; O. Myers [États-Unis] ; B. Tinner [Canada] ; W. Staines [Canada] ; E. Barr [États-Unis] ; K. K. Divine [États-Unis] ; W. Barrington [États-Unis] ; J. Karlsson [États-Unis] | Trigeminal uptake and clearance of inhaled manganese chloride in rats and mice |
002A95 (2005) |
Jasvinder S. Sidhu [États-Unis] ; Yadavendra S. Rajawat [États-Unis] ; Tapan G. Rami [États-Unis] ; Michael H. Gollob [Canada] ; ZHINONG WANG [États-Unis] ; RUIYONG YUAN [États-Unis] ; A. J. Marian [États-Unis] ; Francesco J. Demayo [États-Unis] ; Donald Weilbacher [États-Unis] ; George E. Taffet [États-Unis] ; Joanna K. Davies [Royaume-Uni] ; David Carling [Royaume-Uni] ; Dirar S. Khoury [États-Unis] ; Robert Roberts [Canada] | Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome |